You should not use Wegovy pills if you: Have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Are pregnant or planning to become pregnant (semaglutide should be discontinued at least 2 months before a planned pregnancy) Have a history of serious hypersensitivity reactions to semaglutide Are currently taking another semaglutide-containing product (Ozempic, Rybelsus, injectable Wegovy) or another GLP-1 receptor agonist Your provider will also consider your full medication list and medical history before issuing a prescription
The product also includes a complete B-vitamin complex and electrolytes from sodium and potassium citrate, making it a well-rounded pre-workout option
They can adjust your treatment plan if necessary to protect your kidney health
Phase 2 Clinical Trial Data The landmark Phase 2 trial of retatrutide in obesity was a 48-week, randomized, double-blind, placebo-controlled study published in The New England Journal of Medicine in 2023
Your provider will guide you on a treatment regimen that may include an increase in dose every four weeks.You should not change your dosing regimen or stop taking compounded semaglutide as prescribed without discussing with your provider first
Hims & Hers Action May Be a Tipping Point On Saturday, February 7, Hims & Hers said it would stop offering the pill
